SEC Form 4/A · accession 0001209191-16-114834
Oncotelic Therapeutics, Inc. · OTLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
William D Schwieterman
Officer — President and CEO · Director
Period of report
Mar 21, 2016
Accepted (ET)
Apr 19, 2016 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000908259
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $0.7277 | Mar 21, 2016 | A | 500,000 | A | — | Mar 21, 2026 | Common Stock | 500,000 | 500,000 | D |
Explanation of responses
- F1Dr. Schwieterman was awarded options to purchase OXiGENE, Inc. common stock, $0.01 par value per share (the "Stock Options"), pursuant to the OXiGENE, Inc. 2015 Equity Incentive Plan in connection with his service as President and Chief Executive Officer. The original Form 4 filed on March 23, 2016 (the "Original Form 4") is amended by this Form 4 amendment to correctly reflect the number of Stock Options granted and the number of derivative securities beneficially owned following the reported transaction. No other changes have been made to the Original Form 4.
- F225% of the Stock Options will vest on the first anniversary of the date of grant, and the remainder will vest in 36 substantially equal monthly installments beginning one year and one month after the grant date.